As volatility creeps into Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), investors need to pay close attention to to the factors affecting stock today as its shares are trading 3.58% or 0.21 points down from last closing price of $5.86, reaching $5.65 at last check. The LXRX share price has dropped in 3 of the last 5 days and is down -20.05% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -55,043 shares, and in total 162257 shares valued at $916752 were seen changing hands compared with 217300 shares valued at $1.273 million recorded at the previous session. You should take into consideration that a falling volume on lower prices shows the bearish trend but this is an early indication which means that the LXRX stock is near its bottom.
Lexicon Pharmaceuticals, Inc. (LXRX) shares have notched a 3-month decline of about -20.05%, but has still tumbled -11.75% year to date. By comparison, the stock sank -53.93% over the past 12 months, while it slipped -9.15% over the 1 month. The company’s market cap is around $621.48M, with its short interest ratio standing at 15.63%.
In the current trading session for LXRX, the stock witnessed two major price actions, it rose to a high of $5.89 and was down as much as $5.56 at one point. The high recorded is very low when compared to their 52-week high which is $4.25. The 52-week high is now at -59.41 distance from current price. Their recent low of $13.97 represents a 33.41% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for LXRX is $20, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
The stock of Lexicon Pharmaceuticals, Inc. earned $-0.95 per share in the trailing 12 months and has a P/E ratio of -5.95. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 69.3 and lower compared to the sector’s average of 32.55. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. LXRX also has P/S multiple of 12.69. This is smaller versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 49.5x.
The company recorded an interesting insider purchase transaction by the Director on Jun 28, 2018. A Securities and Exchanges Commission filings show that Public Equities L.P. Invus bought a total of 182,838 LXRX shares that day for a sum of around $2,287,303. Lexicon Pharmaceuticals, Inc. (LXRX) insiders have acquired no shares in the stock within the past three months. In total, individual insiders traded no shares in the business, which makes up 0% of 603,339 shares that were traded over a year. In the past 12 months, insiders have purchased 555,320 shares while the seller parted with 48,019 shares.
LXRX‘s last price was down -22.38% as compared to the average trading price of 50 days recorded at $7.28 while enlarging the period to 200 trading days, the average closing price was $5.99. At present, there are 106.05 million in the total number of common shares owned by the public and among those 105.85 million shares have been available to trade. The percentage of shares being held by the company management was 0.3% while institutions stake was 99.4%. The company has generated positive returns on equity over the last 12 months (376.4%). It managed to keep its gross profit margin at 95.5% over the past 12 months.
When assessing the full upside of the LXRX stock, there is another set of technicals that should be looked into and considered. Its -1.55% decline from moving average of $5.74 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of 0.73 to the stock. With the beta been less than one, this implies that the company shares are theoretically less volatile than the market, something that the traders definitely are keeping an eye on.
Most of the analysts surveyed by Thomson/First Call think quite highly of Lexicon Pharmaceuticals, Inc. — 3 analysts rate the stock as a buy with another 0 rating it strong buy. There are 3 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $19.6667 on shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), which corresponds to 248.08% upside potential than its current market price of $5.65 and implies potential despite the recent drop in the price. However, their current target price has fallen from $19.6667 a month ago and is down handily from the consensus target of $25 a quarter ago.
In the last five years, the EPS of the company has been roughly 4.3%. Though the percentage looks disappointing, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has risen at an average annualized rate of about 95.3 over the last five years. The company recently recorded a drop of -63.8%, but this figure is rather unattractive.
Let’s briefly check the hedge fund interest towards LXRX stock. Clearbridge Investments LLC added position in the company after it grew 3.2% or 1,252,064 shares of its common stock. The hedge fund now owns 1,292,130 shares worth $7,300,535, SEC documents show. FMR LLC cut assets in the stock as 14762745 shares have been sold, reducing its stake by -2.6% to 14,378,914 shares which are currently valued at $81,240,864. In addition, BlueMountain Capital Management LLC recently reported that it now owns 79,368 shares making a total of $448,429 based on the recent price. This refelects a change of 50% in their ownership.